The 1997 ANAO audit reveals that the industry was focused on comparator selection, the incorporation of wider qualitative economic benefits in the evaluation process, and the need to reduce submission churn to accelerate new listings. Sound familiar?
The last audit shows why more process will never lead to faster access
July 26, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Moderna announces positive Phase 3 result for influenza vaccine
July 1, 2025 - - Latest News -
Research lagging for sarcoma, despite accounting for one third of adolescent cancer deaths
July 1, 2025 - - Latest News -
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 - - Latest News -
The real question is why expectations were so high in the first place
July 1, 2025 - - Latest News -
National Pharmacies appoints experienced industry leader as new CEO
July 1, 2025 - - Latest News -
Tetratherix lists on the ASX following successful IPO
June 30, 2025 - - Australian Biotech -
LTR Pharma achieves key FDA milestone through extractables study
June 30, 2025 - - Australian Biotech